CRBUHealthcare · BiotechnologyThe 6 Wall Street analysts covering Caribou Biosciences, Inc. hold a median 12-month price target of $4.5 — +805.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 12 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Caribou Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRBU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +805.6% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 7 Oct 2026 | Brookline Capital | Downgrade | Hold | — |
| 7 Oct 2026 | Leerink Partners | Downgrade | Market Perform | $4.00 → $1.00 |
| 7 Oct 2026 | RBC Capital | Downgrade | Sector Perform | $10 → $1.00 |
| 14 Aug 2026 | B of A Securities | Maintains | Buy | $6.00 → $5.00 |
| 14 Aug 2026 | B of A Securities | Maintains | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $9.00 → $11 |
| 7 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Mar 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Feb 2026 | Clear Street | Initiates | Buy | — |
| 5 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Nov 2025 | Citigroup | Maintains | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2025 | B of A Securities | Maintains | Buy | — |
| 26 Nov 2024 | Citigroup | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRBU appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Caribou Biosciences, Inc. returned −80.0% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 25% of US stocks
Cheaper than 84% of US stocks
Cheaper than 60% of US stocks
Higher than 6% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Caribou Biosciences, Inc. has a market value of $49.3M and an enterprise value of −$19.5M.
Revenue in the twelve months to 30 June 2026: $10.0M. The latest quarter shrank 43.8% year on year.
Net income over the same four quarters: −$103.4M, a −1030.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.08.
Free cash flow in the twelve months to 30 June 2026: −$95.8M.
Trailing P/E: −0.3×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Caribou Biosciences, Inc. employs 97 people — $103K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Caribou Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Caribou Biosciences said it will evaluate strategic alternatives to maximize stockholder value and plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs.
Why it matters — The evaluation and planned discontinuations mark a significant change in Caribou’s programs and strategic direction.
Caribou Biosciences (CRBU) has declined 19.6% over the past four weeks and is now technically in oversold territory. The article suggests that this selling pressure may have exhausted, supported by Wall Street analysts revising earnings estimates higher, indicating a possible trend reversal.
Why it matters — A CRBU watcher would care because the oversold technical condition combined with upward earnings estimate revisions could signal that the stock's recent decline may be coming to an end.
Zacks Investment Research identified CRBU among five top-ranked stocks (alongside ALL, W, BILL, and TWLO) that are likely to beat earnings expectations in their upcoming releases.
Why it matters — A positive earnings-beat outlook from a research firm could draw attention to CRBU ahead of its next quarterly report.
Caribou Biosciences reported a Q2 loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.33 loss and down from a $0.35 per-share loss a year earlier, though revenue lagged estimates.
Why it matters — The narrower-than-expected quarterly loss may signal improving operating performance, while the revenue shortfall highlights top-line headwinds investors in CRBU will want to monitor.
Caribou Biosciences reported its Q2 2026 financial results and presented phase 1 data for vispa-cel at EHA 2026, which showed the therapy's safety, efficacy, and durability are comparable to approved autologous CAR-T cell therapies. The company also presented CaMMouflage dose escalation data for CB-011, with initial dose expansion data expected in the second half of 2026.
Why it matters — A CRBU watcher would care because the EHA 2026 data reinforce vispa-cel's potential to compete with approved CAR-T therapies and provide a timeline for CB-011's next data readout in high-risk multiple myeloma patients.
The 6 Wall Street analysts covering Caribou Biosciences, Inc. have a median 12-month price target of $4.5, with estimates ranging from $1 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Caribou Biosciences, Inc., 2 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caribou Biosciences, Inc. 46 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Caribou Biosciences, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +805.6% from the last close, and Ticker Nerd's factor model ranks Caribou Biosciences, Inc. 46 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Caribou Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $13 over the next 12 months.
Caribou Biosciences, Inc. returned -80.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Caribou Biosciences to Evaluate Strategic Alternatives". Caribou Biosciences said it will evaluate strategic alternatives to maximize stockholder value and plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs.
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform. The company works on off-the-shelf CAR-T and CAR-NK therapies designed to support precise cell engineering for difficult-to-treat diseases. Its current pipeline centers on hematologic malignancies and autoimmune disorders, with programs that include anti-CD19, anti-BCMA, and anti-CD371 cell therapies in clinical development. Caribou Biosciences also applies its gene-editing technology to advance broader research and therapeutic applications in biotechnology. Headquartered in Berkeley, California, the company operates as a single business segment centered on next-generation cell therapy development.
CEO Dr. Rachel E. Haurwitz Ph.D. · 97 employees · United States · https://cariboubio.com
